JP2023530036A5 - - Google Patents
Info
- Publication number
- JP2023530036A5 JP2023530036A5 JP2023517829A JP2023517829A JP2023530036A5 JP 2023530036 A5 JP2023530036 A5 JP 2023530036A5 JP 2023517829 A JP2023517829 A JP 2023517829A JP 2023517829 A JP2023517829 A JP 2023517829A JP 2023530036 A5 JP2023530036 A5 JP 2023530036A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- specified
- sequence specified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032747P | 2020-06-01 | 2020-06-01 | |
| US63/032,747 | 2020-06-01 | ||
| US17/199,205 US11359023B2 (en) | 2020-06-01 | 2021-03-11 | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US17/199,205 | 2021-03-11 | ||
| PCT/US2021/035290 WO2021247607A1 (en) | 2020-06-01 | 2021-06-01 | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023530036A JP2023530036A (ja) | 2023-07-12 |
| JP2023530036A5 true JP2023530036A5 (cg-RX-API-DMAC10.html) | 2023-08-02 |
| JP7650351B2 JP7650351B2 (ja) | 2025-03-24 |
Family
ID=75495114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517829A Active JP7650351B2 (ja) | 2020-06-01 | 2021-06-01 | 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 |
Country Status (20)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021531255A (ja) * | 2018-07-23 | 2021-11-18 | アベクサ バイオロジクス，インク． | 非古典的ｈｌａ−ｉおよびネオアンチゲンを含む複合体を標的とする抗体、およびその使用方法 |
| WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US20250223363A1 (en) * | 2022-04-08 | 2025-07-10 | Tizona Therapeutics, Inc. | Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039218B2 (en) * | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| WO2006113747A2 (en) * | 2005-04-19 | 2006-10-26 | Prediction Sciences Llc | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2010019921A2 (en) * | 2008-08-15 | 2010-02-18 | The Regents Of The University Of California | Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia |
| WO2011035433A1 (en) * | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
| US9206257B2 (en) | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| CN104936985A (zh) | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| CN103773775B (zh) | 2014-01-26 | 2015-11-18 | 江苏省农业科学院 | 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用 |
| KR20170020868A (ko) | 2014-06-20 | 2017-02-24 | 바이오얼라이언스 씨.브이. | 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법 |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| JP7054397B2 (ja) | 2016-06-27 | 2022-04-13 | ジュノー セラピューティクス インコーポレイテッド | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 |
| EP3573997A4 (en) | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| CN112351795A (zh) | 2018-02-23 | 2021-02-09 | 安贝科思生物制剂公司 | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 |
| JP2021531255A (ja) | 2018-07-23 | 2021-11-18 | アベクサ バイオロジクス，インク． | 非古典的ｈｌａ−ｉおよびネオアンチゲンを含む複合体を標的とする抗体、およびその使用方法 |
| US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US10981997B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
-
2020
- 2020-07-10 US US16/926,306 patent/US10981996B1/en active Active
-
2021
- 2021-03-11 US US17/199,205 patent/US11359023B2/en active Active
- 2021-06-01 US US18/000,486 patent/US20240026007A1/en not_active Abandoned
- 2021-06-01 PE PE2022002770A patent/PE20230306A1/es unknown
- 2021-06-01 KR KR1020227046387A patent/KR20230019468A/ko not_active Withdrawn
- 2021-06-01 MX MX2022015114A patent/MX2022015114A/es unknown
- 2021-06-01 JP JP2023517829A patent/JP7650351B2/ja active Active
- 2021-06-01 AU AU2021284275A patent/AU2021284275A1/en not_active Abandoned
- 2021-06-01 IL IL298020A patent/IL298020A/en unknown
- 2021-06-01 EP EP21818102.2A patent/EP4157882A4/en active Pending
- 2021-06-01 CR CR20220652A patent/CR20220652A/es unknown
- 2021-06-01 WO PCT/US2021/035290 patent/WO2021247607A1/en not_active Ceased
- 2021-06-01 AR ARP210101494A patent/AR122501A1/es not_active Application Discontinuation
- 2021-06-01 CN CN202180057742.6A patent/CN116367865A/zh active Pending
- 2021-06-01 BR BR112022024275A patent/BR112022024275A2/pt not_active Application Discontinuation
- 2021-06-01 CA CA3174090A patent/CA3174090A1/en active Pending
- 2021-06-02 TW TW110120100A patent/TW202235439A/zh unknown
-
2022
- 2022-05-13 US US17/663,393 patent/US12173072B2/en active Active
- 2022-11-15 JO JOJO/P/2022/0309A patent/JOP20220309A1/ar unknown
- 2022-11-25 CL CL2022003336A patent/CL2022003336A1/es unknown
- 2022-11-28 DO DO2022000268A patent/DOP2022000268A/es unknown
- 2022-12-19 CO CONC2022/0018426A patent/CO2022018426A2/es unknown
- 2022-12-23 EC ECSENADI202297197A patent/ECSP22097197A/es unknown